Compare Cassava Sciences Inc (FLNA) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Medpace Holdings Inc — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Medpace Holdings Inc trades at $535.89 (market cap $15.11B). The key difference: Medpace Holdings Inc is far larger — about 284.3× Cassava Sciences Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | MEDP | |
|---|---|---|
Market Cap | $53.14M | $15.11B |
Sector | Health | Technology |
52-Week High | $4.64 | $620.59 |
52-Week Low | $1.09 | $308.88 |
Enterprise Value | -$33.43M | $14.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $539.39, up 0.6% today, with a bullish technical outlook supported by moving averages and a neutral RSI. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue grew to $2.53B in 2025, and net income margins remain strong at 17.19%, though valuation ratios like P/E of 33.31 suggest premium pricing. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook: MEDP shows robust profitability and growth potential, but high valuations and legal risks warrant caution. Analyst consensus is mixed with a $497 price target below current levels, indicating limited upside. Key catalysts include Q2 2026 earnings on July 22, 2026, which could drive momentum if results exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
